China Biopharma, Clinical Development, CRO Utilization and Outlook Report 2023: Clinical Trial Characteristics & Clinical Development Outsourcing and Growth
May 31, 2023 03:53 ET
|
Research and Markets
Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Chinese Biopharma, Clinical Development, CRO Utilization and Outlook 2023" report has been added to ResearchAndMarkets.com's offering. This report...
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
May 16, 2023 08:30 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed...
Respiratory Syncytial Virus Marketed and Pipeline Drugs Assessment Report 2023
May 08, 2023 08:43 ET
|
Research and Markets
Dublin, May 08, 2023 (GLOBE NEWSWIRE) -- The "Respiratory Syncytial Virus Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" report has been added to ...
Pharmaceutical Regulatory Affairs in China Training Course: Overview of how to Gain and Maintain a Successful Pharmaceutical Marketing Authorisation (July 4-5, 2023)
April 28, 2023 04:13 ET
|
Research and Markets
Dublin, April 28, 2023 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs in China Training Course" conference has been added to ResearchAndMarkets.com's offering.This seminar will provide...
Global Drug Discovery Services Markets, 2023-2028: Burgeoning Opportunities with Patent Expiries of Key Biologics and Rising Demand for Specialized Testing Services
April 17, 2023 09:48 ET
|
Research and Markets
Dublin, April 17, 2023 (GLOBE NEWSWIRE) -- The "Global Drug Discovery Services Market 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global Drug discovery services...
Latozinemab (AL001): Alector's Wholly-owned Humanized Recombinant Monoclonal Antibody - Emerging Drug Insights and Market Forecasts 2019-2022 & 2023-2032
April 13, 2023 10:48 ET
|
Research and Markets
Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Latozinemab (AL001) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.The report provides...
Zilucoplan: A Selective C5 (Complement Component 5) Peptide Inhibitor Under Clinical Development by UCB Biopharma - Emerging Drug Insight and Market Forecasts to 2032
April 13, 2023 10:44 ET
|
Research and Markets
Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Zilucoplan Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.The report provides...
Zunsemetinib (ATI-450) Emerging Drug Insights and Market Forecasts, 2032
April 13, 2023 10:33 ET
|
Research and Markets
Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Zunsemetinib (ATI-450) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.The report...
Povorcitinib (INCB054707): A Selective JAK1 Inhibitor Being Developed by Incyte Corporation - Emerging Drug Insight and Market Forecasts 2019-2022 & 2023-2032
April 13, 2023 10:28 ET
|
Research and Markets
Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Povorcitinib (INCB054707) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.The report...
ENSPRYNG Emerging Drug Insight and Market Forecast 2023- 2032
April 10, 2023 04:03 ET
|
Research and Markets
Dublin, April 10, 2023 (GLOBE NEWSWIRE) -- The "ENSPRYNG Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering."ENSPRYNG Emerging Drug Insight...